David Brinton

Cooley advised Impact Analytics, a provider of the industry’s most innovative retail, grocery, consumer packaged goods, and supply chain-focused planning and merchandising software suite, on the close of its $40 million growth financing.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Cooley advised Instil Bio on its $368 million initial public offering of 18,400,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Instil Bio, whose securities now trade on the Nasdaq Global Market under the symbol TIL, is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocytes therapies for the treatment of patients with cancer. Partners Div Gupta, Madison Jones and Brent Siler led the Cooley team.

Cooley advised Xos Trucks on its agreement to combine with NextGen Acquisition Corporation, a publicly traded special purpose acquisition company or SPAC - a transaction with an equity value of $1.296 billion. The combined company will remain publicly listed on Nasdaq under the symbol "XOS". Partners Garth Osterman and David Peinsipp led the Cooley team advising Xos Trucks, a leading manufacturer of fully electric battery mobility systems for commercial fleets.

Read more

Cooley advised Taysha Gene Therapies on its $181.0 million initial public offering of 9,050,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Taysha, whose securities now trade on the Nasdaq Global Select Market under the symbol “TSHA,” is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. Partners Div Gupta, Darren DeStefano an Brian Leaf led the Cooley team.